(Q34377753)

1 August 2017

Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity (English)

1 reference

1 August 2017

1 reference

ChEBI release 2020-05-28

4

Christine M Fandozzi

1 reference

1 August 2017

Craig A Coburn

1

1 reference

1 August 2017

Peter T Meinke

2

1 reference

1 August 2017

Wei Chang

3

1 reference

1 August 2017

Donald J Graham

5

1 reference

1 August 2017

Bin Hu

6

1 reference

1 August 2017

Qian Huang

7

1 reference

1 August 2017

Stacia Kargman

8

1 reference

1 August 2017

Joseph Kozlowski

9

1 reference

1 August 2017

Rong Liu

10

1 reference

1 August 2017

John A McCauley

11

1 reference

1 August 2017

Amin A Nomeir

12

1 reference

1 August 2017

Richard M Soll

13

1 reference

1 August 2017

Joseph P Vacca

14

1 reference

1 August 2017

Dahai Wang

15

1 reference

1 August 2017

Hao Wu

16

1 reference

1 August 2017

Bin Zhong

17

1 reference

1 August 2017

David B Olsen

18

1 reference

1 August 2017

Steven W Ludmerer

19

1 reference

1 August 2017

14 October 2013

1 reference

1 August 2017

1 reference

1 August 2017

8

1 reference

1 August 2017

12

1 reference

1 August 2017

1930-1940

1 reference

Evolving epidemiology of hepatitis C virus

1 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300343

7 January 2021

Understanding the hepatitis C virus life cycle paves the way for highly effective therapies.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300343

7 January 2021

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300343

7 January 2021

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300343

7 January 2021

Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300343

7 January 2021

HCV NS5A inhibitors in development

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300343

7 January 2021

NS5A inhibitors in the treatment of hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300343

7 January 2021

Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300343

7 January 2021

TARGETING THE NS5A PROTEIN OF HCV: AN EMERGING OPTION.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300343

7 January 2021

NS5A--from obscurity to new target for HCV therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300343

7 January 2021

Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300343

7 January 2021

Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300343

7 January 2021

Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300343

7 January 2021

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300343

7 January 2021

Identification of Hepatitis C Virus NS5A Inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300343

7 January 2021

Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300343

7 January 2021

Robust Antiviral Efficacy upon Administration of a Nucleoside Analog to Hepatitis C Virus-Infected Chimpanzees

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300343

7 January 2021

A transient cell-based phenotype assay for hepatitis C NS3/4A protease: application to potency determinations of a novel macrocyclic inhibitor against diverse protease sequences isolated from plasma infected with HCV.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300343

7 January 2021

A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300343

7 January 2021

MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300343

7 January 2021

Identifiers

DOI

10.1002/CMDC.201300343

1 reference

1 August 2017

1 reference